Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 108672
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108672
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108672
DEAD/H-box RNA helicase 10 promotes pancreatic cancer cell proliferation via ribonucleotide reductase M2
Zhi-Sheng Qiu, Cheng-Lou Zhu, Yong-Li Hu, Ming-Xu Da, The First Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu Province, China
Zhi-Sheng Qiu, Ji-Chun Ma, Ming-Xu Da, Department of Oncology Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Xiao-Chun Wang, Department of Gastroenterology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Author contributions: Qiu ZS and Da MX conceived and designed the study; Qiu ZS performed some experiments, analyzed the data, and wrote the manuscript; Wang XC performed some cell experiments and revised the manuscript; Ma JC, Zhu CL, and Hu YL guided the experiments; All the authors have read and approved the final version of the manuscript.
Supported by National Natural Science Foundation of China, No. 82160588; Health Commission of Gansu Province, No. GSWSKY2021-032; Natural Science Foundation of Gansu Province, No. 24JRRA585; and Gansu Provincial Hospital Science and Technology Innovation Platform Fund Project, No. 21GSSYB-23.
Institutional review board statement: The study was approved by the Ethics Committee of Gansu Provincial Hospital (approval number: 2023-391), with informed consent obtained from all participants.
Institutional animal care and use committee statement: This animal study was approved by the Laboratory Animal Ethics Committee of Shanghai Genechem Co., Ltd., No. GSZE0368849.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request at ldyy_damx@lzu.edu.cn.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Xu Da, Professor, The First Clinical Medical College, Lanzhou University, No. 222 Tianshui South Road, Chengguan District, Lanzhou 730000, Gansu Province, China. ldyy_damx@lzu.edu.cn
Received: April 21, 2025
Revised: May 23, 2025
Accepted: July 18, 2025
Published online: September 15, 2025
Processing time: 148 Days and 16.1 Hours
Revised: May 23, 2025
Accepted: July 18, 2025
Published online: September 15, 2025
Processing time: 148 Days and 16.1 Hours
Core Tip
Core Tip: This study elucidates the role of DEAD-box RNA helicase 10 (DDX10) in pancreatic cancer (PC) progression. Through bioinformatics analysis, tissue microarray evaluation, and in vitro assays, we discovered that DDX10 is overexpressed in PC tissues compared to non-tumor tissues. Knockdown of DDX10 significantly inhibited cell proliferation, invasion, and migration while promoting apoptosis. Mechanistic investigations revealed that DDX10 regulates key oncogenes, including RRM2, which counteracts the growth-inhibitory effects of DDX10 knockdown. Importantly, DDX10 expression was found to negatively correlate with patient survival rates. These findings highlight DDX10 as a potential therapeutic target for PC.